Post-Marketing Safety Assessment of CAR T-Cell Therapies: Analysis of Individual Case Safety Reports in the VigiBase

被引：0
|
作者：
Alrasheed, Meshael [1 ]
Alhawas, Solaiman [1 ]
Alorf, Nora S. [2 ]
Al-Fadel, Nouf [3 ]
Alharbi, Fawaz [3 ]
机构：
[1] Saudi Food & Drug Author SFDA, Riyadh, Saudi Arabia
[2] Saudi Food & Drug Author, Riyadh, Saudi Arabia
[3] Saudi Food & Drug Author, Drug Sect, Drug Safety & Risk Management Dept, Execut Directorate Pharmacovigilance, Riyadh, Saudi Arabia
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2024年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1185
引用
收藏
页码：533 / 534
页数：2
相关论文
共 50 条
  • [21] Adverse drug reactions of statins in a paediatric population: A descriptive analysis of individual case safety reports from Vigibase
    Conte, Cecile
    Vert, Charlotte
    Rousseau, Vanessa
    Chebane, Leyla
    Montastruc, Jean Louis
    Durrieu, Genevieve
    Olivier, Pascale
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 391 - 391
  • [22] Post-marketing safety of Adagrasib: a disproportionality analysis based on the FAERS database
    Shi, Zheng
    Yu, Xiayao
    Zhao, Yifan
    Shao, Keda
    Xu, Chunwei
    Song, Zhengbo
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [23] Adverse drug reactions of statins in a paediatric population: a descriptive analysis of individual case safety reports from VigiBase®
    Vert, C.
    Conte, C.
    Rousseau, V.
    Chebane, L.
    Montastruc, J. L.
    Durrieu, G.
    Olivier, P.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2018, 32 : 67 - 67
  • [24] Toxicity spectrum of taxanes: a safety analysis from pre-marketing to post-marketing
    Zhao, Qiuling
    Nian, Zilin
    He, Yimin
    Lai, Lijun
    Liu, Wenbin
    Huang, Shengqiang
    Yang, Lin
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [25] Pediatric post-marketing safety systems in North America: assessment of the current status
    McMahon, Ann W.
    Wharton, Gerold T.
    Bonnel, Renan
    DeCelle, Mary
    Swank, Kimberley
    Testoni, Daniela
    Cope, Judith U.
    Smith, Phillip Brian
    Wu, Eileen
    Murphy, Mary Dianne
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 (08) : 785 - 792
  • [26] Safety of direct oral anticoagulants reversal agents in older patients: an analysis of individual case safety reports of adverse drug reaction from VigiBase®
    Giada Crescioli
    Niccolò Lombardi
    Elena Arzenton
    Nicoletta Luxi
    Stefano Fumagalli
    Roberto Bonaiuti
    Costanza Cacini
    Guido Mannaioni
    Gianluca Trifirò
    Ugo Moretti
    Alfredo Vannacci
    Aging Clinical and Experimental Research, 37 (1)
  • [27] Vortioxetine's post-marketing safety profile determined through cluster analysis of global adverse event reports
    Ekhart, Corine
    van Hunsel, Florence
    van Puijenbroek, Eugene
    Chandler, Rebecca
    Meldau, Eva-Lisa
    Noren, Niklas
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 497 - 497
  • [28] Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
    Sakata, Yukinori
    Matsuoka, Toshiyuki
    Ohashi, Satoshi
    Koga, Tadashi
    Toyoda, Tetsumi
    Ishii, Mika
    DRUGS-REAL WORLD OUTCOMES, 2019, 6 (01) : 27 - 35
  • [29] CAR T-cell therapy: Balance of efficacy and safety
    S. V. Kulemzin
    V. V. Kuznetsova
    M. Mamonkin
    A. V. Taranin
    A. A. Gorchakov
    Molecular Biology, 2017, 51 : 237 - 250
  • [30] CAR T-cell therapy: Balance of efficacy and safety
    Kulemzin, S. V.
    Kuznetsova, V. V.
    Mamonkin, M.
    Taranin, A. V.
    Gorchakov, A. A.
    MOLECULAR BIOLOGY, 2017, 51 (02) : 237 - 250
12345